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                  1.  INTRODUCTION 
 
Herbalism  
Herbalism is the study of botany and use of plants intended for medicinal purposes or 
for supplementing a diet. Herbalism is also known as botanical medicine, medicinal 
herbalism, herbal medicine, herbology, herblore, and phytotherapy1 .  
 
History of Herbal Medicine: 
   Plants had been used for medicinal purposes long before recorded history. Ancient 
Chinese and Egyptian papyrus writings describe medicinal uses for plants as early as 
3,000 BC. Indigenous cultures (such as African and Native American) used herbs in 
their healing rituals, while others developed traditional medical systems (such as 
Siddha, Ayurveda, Unani and TCM) in which herbal therapies were used2. The 
consumption of plant-based medicines and other botanicals in the West has increased 
manifold in recent years. About two centuries ago, our medicinal practices were 
largely dominated by plant-based medicines. However, the medicinal use of herbs 
went into a rapid decline in the West when more predictable synthetic drugs were 
made commonly available. In contrast, many developing nations continued to benefit 
from the rich knowledge of medical herbalism. For example, Siddha & Ayurveda 
medicines in India, Kampo Medicine in Japan, traditional Chinese medicine (TCM), 
and Unani medicine in the Middle East and South Asia are still used by a large 
majority of people3.  
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2. Herbal Medicine 
Herbal medicines are being used by about 80% of the world population primarily in 
the developing countries for primary health care. They have stood the test of time for 
their safety, efficacy, cultural acceptability and lesser side effects. Ancient literature 
also mentions herbal medicines for age-related diseases namely memory loss, 
osteoporosis, osteoarthritis, diabetes, immune and liver disorders, etc. for which no 
modern medicine or only palliative therapy is available4. The chemical constituents 
present in them are a part of the physiological functions of living flora and hence they 
are believed to have better compatibility with the human body5. There are over 1.5 
million practitioners of traditional medicinal system using medicinal plants in 
preventive, promotional and curative applications. Medicinal plants have attracted the 
attention of not only professionals from various systems of medicine, but also the 
scientific communities belonging to different disciplines, plants are promising source 
of herbal formulation6. The use of herbal drugs due to toxicity and side effects of 
allopathic medicines, has led to rapid increase in the number of herbal drug 
manufacturers. For the past few decades, herbal drugs have been more and more 
consumed by the people with no prescription. These drugs have survived real world 
testing and thousands of years of human testing. Some drugs have been discontinued 
due to their toxicity, while others have been modified or combined with additional 
herbs to counterbalance side effects7. 
 
 Advantages of Herbal Drugs 
 high Low/Minimum cost 
 complete accessibility 
 enhanced tolerance 
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 More protection 
 fewer side-effects 
 Potency and efficiency is very high. 
Disadvantages of Herbal Drugs 
 Not able to cure rapid sickness and accidents 
 Risk with self-dosing 
 Complexity in standardizations 
Role of herbals in modern human era 
Many of the currently available to physicians have a long history of use as herbal 
remedies. The who estimate that 80 percent of the world‟s population presently use 
herbal medicine  for some aspect of primary health care .in fact ,according to the 
world health organization ,approximately 25% of modern drugs used in the united 
states have been derived from plants. 
Among the 120 active compounds currently isolated from the higher plants and 
widely used in modern medicine today, 80 percent shows a positive correlation 
between their modern therapeutic use and the traditional use of the plants from which 
they are derived8. 
1. More than two thirds of the world‟s plant species –at least 35,000 of which are 
estimated to have medicinal value –come from the developing countries. 
2. At least  7,000 medicinal compounds in the modern pharmacopoeia are derived 
from plats 
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The Challenges in Herbal Medicines:9  
  A key challenge is to objectively assess conflicting toxicological, epidemiological, 
and other data and the verification of herbal materials used. The following key issues 
remain. 
 Management within ranges of risk 
  Communication of uncertainty 
  Pharmacological, toxicological, and clinical documentation 
  Pharmacovigilance  
  Understanding why addition of harmful additives works 
  evaluating “drug” interactions 
  Constraints with clinical trials and people available 
 Standardization 
 Safety, and efficacy assessment 
 
The evaluation of new herbal products consists of six steps: 
              1. Characteristics of new substances 
   2. History and pattern of use 
   3. Any adverse reaction 
  4. Biological action 
  5. Toxicity  
  6. Clinical trial data 
The Constraints in Herbal Medicines: 
      Constraints associated with the handing of medicinal plants10. 
 Indiscriminate harvesting and poor post-harvest treatment practices. 
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 Lack of research on the development of high-yielding varieties, domestication 
etc. 
 Poor agriculture and propagation methods. 
 Inefficient processing techniques leading to low yields and poor quality 
products. 
 Poor quality control procedures. 
 Lack of current good manufacturing practices. 
 Lack of R & D on product and process development. 
 Difficulties in marketing. 
 Lack of trained personnel and equipment. 
 Lack of facilities to fabricate equipment locally. 
 In addition, the processing of herbs, such as heating or boiling, may alter the 
dissolution rate, or even the pharmacological activity of the organic 
constituents. 
 Similarly, a host of environmental factors, including soil, altitude, seasonal 
variation in temperature, atmospheric humidity, length of daylight, rainfall 
pattern, shade, dew, and frost conditions, may affect the levels of components 
in any given batch of an herb. 
 Other factors, including infections, insects, planting density, competition with 
other plant species, seeding time, and genetic factors, play an important role. 
 Plant collection for the use in botanicals is one of the factors of concern for 
quality. Plants collected in the wild may include non-targeted species, 
especially either by accidental substitution or intentional adulteration. 
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 Adulteration of herbal products can be made in various ways; commonly, 
adulteration is made by substituting other easily available or cheap plant 
species or sometimes by spiking of a product with synthetic constituents. 
 
Factors affecting quality & purity of Herbal Medicines:11,12   
   
1.Drug adulteration 
Adulteration may be defined as mixing or substituting the original drug material with 
other spurious, inferior, defective, spoiled, useless other parts of same or different 
plant or harmful substances or drug which do not confirm with the official standards.  
Adulteration may takes place by two ways: 
- Direct or intentional adulteration 
- Indirect or unintentional adulteration 
Examples for Adulteration, 
A. With artificially manufactured materials, e.g. nutmeg is adulterated with basswood 
prepared to the required shape and size, the colored paraffin wax is used in place of 
beeswax. 
B. With inferior quality materials, e.g. Belladonna leaves are substituted with 
Ailanthus leaves, papaya seeds to adulterate Piper nigrum. 
C. With harmful / fictitious substances drugs, e.g. Pieces of amber colored glass in 
colophony, limestone in asafetida, lead shot in opium, white oil in coconut oil, cocoa 
butter with stearin or paraffin. 
 
D. Adulteration of powders, e.g. powder liquorice or gentian admixed with powder 
olive stones, under the name of cinchona. Etc 
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2. Faulty collection 
3. Imperfect preparation Non removal of associated structures e.g. stems are collected 
with leaves, flowers, fruits. Non-removal of undesirable parts or structures e.g. cork 
should be removed from ginger rhizome. 
Proper drying conditions should be adhered. Improper drying may lead to 
unintentional adulteration e.g. if digitalis leaves are dried above 65 °C decomposition 
of glycosides by enzymatic hydrolysis. 
4. Incorrect storage Deterioration happens especially during storage, leading to the 
loss of the active ingredients, production of metabolites with no activity and, in 
extreme cases, the production of toxic metabolites. Physical factors such as air 
(oxygen), humidity, light, and temperature can bring about deterioration directly or 
indirectly. 
5. Gross substitution with plant material 
6. Substitution with exhausted drugs 
  
The Opportunities in Herbal Medicines:13 
1. Medicinal plants cultivation. 
2. Medicinal plants Exports. 
3. In Drug Manufacturing Companies. 
4. Teaching profession - Herbal medicine is being taught more in medical schools and 
pharmacy schools. 
5. In the field of Plant monographs 
6. Drug inspectors in ISM. 
7. Medical taxonomist 
8. Pharmacognosist. 
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9. Herbalist & Chiropractors 
10. AYUSH practitioners , Doctors 
11. SRF & JRF in Clinical trials. 
12. Clinical and Research opportunities- Without doubt, the therapeutic potential of 
many herbs is yet to be fully discovered. Example, Recent discovery of „artemisinins‟, 
new class of anti-malarial drugs, in Chinese herbs supports this assertion. 
13. Carrier options in the various newer fields. E.g. Molecular biology, Nano 
technology etc. 
  
   PSORIASIS 
Psoriasis is a long-lasting autoimmune disease which is characterized by 
patches of abnormal skin14.These skin patches are typically red, itchy, and scaly. They 
may vary in severity from small and localized to complete body coverage15. Injury to 
the skin can trigger psoriatic skin changes at that spot, which is known as the Koebner 
phenomenon16. 
                                              NORMAL SKIN FIG: 1 
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                                   FIG: 2   PSORIASIS SKIN 
                       
 
Epidemiology 
 Psoriasis is found worldwide, affecting approximately 1% to 3% of the population. 
Men and women are equally affected. Psoriasis exhibits a bimodal distribution with a 
peak between 15 and 20 years of age and another peak between 55 and 60 years17.  On 
the basis of the bimodal distribution of the age at onset and inheritance, two types of 
psoriasis have been discussed. Type I psoriasis (approximately 65% of the psoriasis 
population) is associated with onset below the age of 40, a positive family history of 
psoriasis, a preceding streptococcal sore throat, and guttate lesions. Type II psoriasis 
(35% of psoriasis patients) appears to be associated with a population with onset after 
the age of 40 years and with no family history of psoriasis. Type II is not linked to a 
preceding infectious trigger. The dominate clinical picture is chronic plaques and an 
association with nail and joint involvement has been described18. 
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Clinical features  
There are several psoriasis phenotypes. The most common clinical variant is 
psoriasis vulgaris, which affects approximately 85 to 90% of all patients with the 
disease. Psoriasis vulgaris is characterised by raised, well-demarcated, erythematous 
plaques with adherent silvery scale. The areas that are affected the most are the 
elbows, knees, sacral region and scalp. Other predilection sites include hands, feet, 
nails and the intertriginous areas (groins, axilla, umbilicus, crena ani, retroauricular 
folds)19. The psoriasis plaques in intertriginous areas are characterised by an oozing, 
red inflammation without scaling. The true incidence of intertriginous psoriasis is 
unknown. In a study by Farber et al20. it was found that 44 % of the psoriasis patients 
had perianal involvement, and in a Swedish study by Inerot et al21 . 
             
Types  of  Psoriasis22,23 
     Plaque Psoriasis 
   This is the most common type. About 8 in 10 people with psoriasis have this kind. You 
may hear your doctor call it "psoriasis vulgaris." 
Plaque psoriasis causes raised, inflamed, red skin covered with silvery, white scales. 
These patches may itch and burn. 
     Elbow, Knee, Scalp, Lower Back  
   Guttate Psoriasis 
This type often starts in children or young adults. It happens in less than 2% of cases. 
Guttate psoriasis causes small, pink-red spots on your skin. 
 Trunk 
                                              INTRODUCTION 
 
DEPARTMENT OF PHARMACOGNOSY, MMC. Page 11 
 
 Upper arms 
 Thighs 
 Scalp 
Inverse Psoriasis 
This type shows up as areas that are bright red, smooth, and shiny, but don't have scales. 
It's usually found in these locations: 
 Armpits 
 Groin 
 Under the breasts 
 Skin folds around the genitals and buttocks 
Pustular Psoriasis 
This kind of psoriasis is uncommon and mostly appears in adults. It causes pus-filled 
bumps (pustules) surrounded by red skin. These may look infectious, but are not. This 
type may show up on one area of your body, such as the hands and feet. Sometimes it 
covers most of your body, which is called "generalized" pustular psoriasis. Generalized 
pustular psoriasis can cause: 
 Fever 
 Chills 
 Nausea  
 Fast heart rate 
 Muscle weakness 
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Erythrodermic Psoriasis 
This type is the least common, but it's very serious. It affects most of your body and 
causes widespread, fiery skin that appears burned.  
 Severe itching, burning, or peeling 
 A faster heart rate 
 Changes in body temperature 
Nail  Psoriasis 
  Up to half of those with psoriasis have nail changes. This is even more common in 
people who have psoriatic arthritis, which affects your joints.Common symptoms 
include: 
 Pitting of your nails 
 Tender, painful nails 
 Separation of the nail from the bed 
 Color changes (yellow-brown) 
 Chalk-like material under your nails 
Psoriatic Arthritis 
This is a condition where you have both psoriasis and arthritis (joint inflammation). In 
70% of cases, people have psoriasis for about 10 years before developing psoriatic 
arthritis. About 90% of people with it also have nail changes. The most common 
symptoms are: 
 Painful, stiff joints that are worse in the morning and after rest 
 Sausage-like swelling of the fingers and toes 
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 Warm joints that may be discolored 
 
 
             
FIG :3 PLAQUE PSORIASIS             FIG:4   NAIL PSORIASIS                       
             
                    FIG:5    Guttate Psoriasis                                      FIG:6   Pustular psoriasis 
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            FIG:7  Erythrodermic Psoriasis                   FIG:8  Psoriatic Arthritis 
 
              
              FIG:9   Inverse psoriasis 
Histological features  
      The psoriasis scales are a result of a hyperproliferative epidermis with premature 
keratinocyte maturation and incomplete cornification with retention of nuclei within 
the cells of the stratum corneum (parakeratosis). The mitotic rate of the basal 
keratinocytes is increased and causes thickening of the epidermis. The redness of the 
lesions is due to increased numbers of tortuous capillaries that reach the skin surface. 
There is an immune cell infiltrate composed of dendritic cells and CD4+ Th cells 
within the upper papillary dermis, and neutrophils and CD8+ Th cells within the 
epidermis24. Neutrophilic granulocytes form characteristic Munro‟s microabscesses. 
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Immunopathogenesis  
   The pathogenesis of psoriasis is a complex interaction among genetic, 
immunological, and environmental components. It was previously assumed that Th1 
cells played the dominant role in the initiation and maintenance of psoriasis but, in 
recent years, the view has changed in favour of a Th17 mediated disease. Innate 
immune cells produce key cytokines (TNF-α, IFN-α, IFN-Ȗ, IL-1ȕ, and IL-6) that 
activate dendritic cells. Activated dendritic cells present antigens and secrete 
mediators such as IL-12 and IL-23, leading to the differentiation of Th1 and Th17. IL-
23 serves as a key master cytokine regulator. T cells secrete mediators (e.g., IL-17 and 
IL-22) that activate keratinocytes and induce the production of antimicrobial peptides, 
proinflammatory cytokines and chemokines. These mediators feed back into the 
proinflammatory disease cycle and shape the inflammatory infiltrate25. 
Genetics  
     The mode of inheritance of psoriasis is complex. Several susceptibility loci for 
psoriasis vulgaris (PSORS) have been identified, but the major genetic determinant of 
psoriasis is PSORS1, which is located within the major histocompatibility complex 
(MHC) on chromosome 6p. Current data suggest that HLA-Cw6 is the susceptibility 
allele within PSORS1. This association is particularly strong in patients with early 
onset psoriasis. One of the most important features of HLA-C is its capacity to 
regulate both innate and adaptive responses at the levels of both antigen presentation 
and natural killer cell regulation26.  
Environmental triggers  
      Psoriasis can be provoked or exacerbated by a variety of different environmental 
factors, particularly infections and drugs. Streptococcal infection is strongly 
associated with guttate psoriasis. In a study of Mallbris et al27.  acute streptococcal 
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pharyngitis was verified in 63% of the patients with guttate phenotype at disease 
onset. The use of various drugs such as lithium, ȕ-blockers, angiotensin-converting 
enzyme inhibitors, antimalarial agents and IFN-α has also been associated with 
induction or deterioration of the disease28.  
Severe acute mental stress can also precede the debut of psoriasis. Smoking has been 
discussed as a risk factor for psoriasis. Several studies have shown a link between 
psoriasis and cigarette smoking; patients with psoriasis are at least twice as likely to 
smoke cigarettes than the general population, and occasional reports have shown that 
smoking has a negative effect on psoriasis.  Heavy tobacco intake also confers an 
increased risk of more clinically severe disease. Physical trauma (e.g. surgical 
incisions and tattoos) can give rise to the Koebner phenomenon29.  The Koebner 
phenomenon constitutes psoriasis plaques that form at the site of a skin injury, and 
usually occurs within one to two weeks of injury to the dermis. 
Microorganisms  
     Various microorganisms have been associated with the provocation and/or 
exacerbation of psoriasis. Certain strains of Staphylococcus aureus can produce 
enterotoxin and one theory is that exacerbation of psoriatic lesions is most likely 
mediated via toxin secretion30. The enterotoxins are highly potent activators of T 
cells. Due to the ability of the staphylococcal enterotoxins to activate a high frequency 
of T cells, they have been designated as Superantigens. Superantigens simultaneously 
bind to MHC class II on APCs and to the TCR on T cells. This cross-linking of APCs 
and T cells results in a polyclonal activation of CD4+ and CD8+ T cells. This leads to 
a massive T cell proliferation and an excessive production of cytokines31. 
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Assessment tools  
    In clinical trials, a large variety of assessment tools have been used to evaluate the 
severity of psoriasis, but there is a lack of standardization32.  In recent years, the 
introduction of quality of life instruments has improved psoriasis evaluation, but there 
is a need for consensus in order to make valid comparisons between studies. In a 
review article it was found that in randomised controlled trials, the Psoriasis Area and 
Severity Index (PASI) was the most commonly used measure to describe the extent of 
psoriasis and  the Dermatology Life Quality Index (DLQI) was the most common tool 
for measuring quality of life33. 
Psoriasis Area and Severity Index  
    The Psoriasis Area and Severity Index (PASI) is a widely used tool for the 
measurement of the severity of psoriasis34. The PASI combines the assessment of the 
severity of lesions and the area affected, into a single score within the range of 0 to 
72. The body is divided into four sections: head (10% of the body area), arms (20%), 
trunk (30%) and legs (40%). Each of these areas is scored separately, and the four 
scores are then combined. For each section, the percentage of the area of skin 
involved is estimated and then transformed into a grade from 0 to 6. The PASI is the 
most validated objective method to measure the severity of psoriasis and has a high 
intra-rater reliability and a good interobserver correlation when used by trained 
assessors. The PASI system is sensitive to changes and reflects disease improvement 
or deterioration, although the sensitivity to change for small areas of involvement is 
poor35. PASI 75 is a widely used concept, meaning the percentage of patients 
achieving a 75% improvement in PASI from baseline to the primary endpoint, usually 
12 to 16 weeks of treatment. Achieving a 75% improvement in the PASI is considered 
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to be successful treatment. PASI 50 (50% improvement) and PASI 90 (90% 
improvement) are sometimes also used. 
Body Surface Area  
 The Body Surface Area (BSA) is an instrument to estimate the extent of psoriasis 
involvement, calculating one palm of the hand represent 1% of the total body surface 
area.  The advantages of BSA are that it is quick and convenient to use, with a low 
test-retest variability for the same observer. However, there is moderately high 
interrater variability and the method is likely to overestimate the extent of psoriatic 
lesions36.  
Dermatology Life Quality Index  
  The Dermatology Life Quality Index (DLQI) is a ten-item questionnaire evaluating 
the quality of life in patients with dermatological diseases.  It consists of six 
subscales: symptoms and feelings, daily activities, leisure, work and school, personal 
relationships and treatment satisfaction. The DLQI can give a total score of 30 with a 
higher score indicating a poorer quality of life. An estimate of the minimal clinically 
important difference of the DLQI total score is a 5 point improvement. However, if 
patients score less than 5 points at baseline, the definition of a clinically meaningful 
response is expanded to include patients who achieved a DLQI total score of 0.  A set 
of intervals of DLQI scores is proposed: 0-1=no effect at all on patient‟s quality of 
life, 2-5=small effect, 6-10=moderate effect, 11-20=very considerable effect and 21-
30=extremely substantial effect. The reliability and validity of the DLQI is well-
established37. 
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Short Form -36  
    The Short Form-36 (SF-36) is a general health status instrument and includes one 
multi-item scale that is applicable to research, general population surveys and health 
policy evaluations. The SF-36 is used in clinical trials and has shown good reliability 
and validity for psoriasis38. The SF-36 is divided into physical health, subdivided into 
physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) 
and into mental health subdivided into vitality (VT), social functioning (SF), role-
emotional (RE) and mental health (MH). The SF-36 consists of eight scaled scores, 
which are the weighted sums of the questions in their section. Each scale is directly 
transformed into a 0-100 scale on the assumption that each question carries equal 
weight.  
Visual Analogue Scale  
      The Visual Analogue Scale (VAS) is a 100-millimetre horizontal line with 
descriptive phrases representing extremes of sensation placed at either end. The 
subject places a mark on the 100 mm line at the most appropriate point. The VAS is a 
tool that is often used to measure subjective phenomena. It has shown a high level of 
reliability  and validity in terms of assessing pain. The VAS has previously been used 
in different psoriasis studies, mainly to reflect the intensity of itching and in one study 
it was also used to measure the patient‟s self-assessment of the severity of his/her 
psoriasis and its impact on quality of life39.  
 Treatment goals  
    The treatment strategy is based on disease severity. The European consensus states 
the definition of disease severity and treatment goals for psoriasis. Mild psoriasis is 
defined as BSA ≤10, PASI ≤10 and DLQI ≤10. Moderate to severe psoriasis is 
defined as BSA >10 or PASI >10 and DLQI >10. Treatment goals (assessed after 10-
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16 weeks) are a reduction of PASI ≥75% and DLQI 0 or 1.  If a treatment regimen 
results in a reduction of PASI ≥75% or PASI ≥50% to <75% combined with a DLQI 
≤5, treatment is successful and therapy should be continued. When there is a 
reduction in PASI <50% or PASI ≥50% to <75% combined with a DLQI >5, 
treatment modifications should be considered, including increasing the drug dose, 
reducing intervals between drug doses, combining therapies or changing the drug40.  
Topical treatment  
 Emollients  
   Emollients are used to soften scaling and reduce irritation. The treatment has a 
positive effect on skin hydration and acts as a barrier function in psoriasis patients41.   
 Corticosteroids 
 Corticosteroids have an anti-inflammatory and immunomodulating effect. 
Corticosteroids inhibit different proinflammatory cytokines such as TNF-α. 
Corticosteroids with a low to mild potency are used for intertriginous psoriasis and 
face lesions. Potent and super potent corticosteroids are used on the body and the 
scalp. There has been concern regarding the long-term use of corticosteroids. Side-
effects that may occur include cutaneous atrophy and the development of striae. There 
is also a possibility of hypothalamic–pituitary–adrenal axis suppression occurring 
with prolonged use of excessive quantities of corticosteroids42. 
  
Calcipotriol  
    Calcipotriol is a vitamin D analogue affecting epidermal proliferation and 
differentiation. Calcipotriol is used for plaque psoriasis. Calcipotriol in a fixed 
combination with betamethasone dipropionate has a faster onset of action than 
monotherapy  Calcipotriol can cause irritant reactions43.  
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Phototherapy  
  Ultraviolet B  
      The mechanism of action of Ultraviolet B (UVB) treatment is not fully 
understood. The number of epidermal T lymphocytes and dendritic cells (DCs) 
decrease and there is a reduction in keratinocyte proliferation. UVB treatment is a 
standard treatment for moderate to severe plaque psoriasis and guttate psoriasis. The 
former use of broad-band UVB (BB-UVB) (290–320 nm) is now often replaced by 
narrow-band UVB (NB-UVB) (311±2 nm). The most common side effects of UVB 
therapy are erythema and burning. BB-UVB is not thought to lead to a risk of 
developing skin cancer but the risk of NB-UVB is under debate. No significant 
association between NB-UVB treatment and BCC, SCC or melanoma has yet been 
seen, but ongoing risk assessments are essential44. 
Psoralen + Ultraviolet A  
    PUVA treatment is psoralen (oral or bath) in combination with Ultraviolet A (320-
400 nm). Psoralen is a compound in a family of natural products known as 
furocoumarins. Psoralen intercalates into the DNA and, on exposure to ultraviolet 
UVA radiation, form covalent interstrand cross-links with thymine, inducing 
apoptosis. Exposure to more than 350 oral PUVA treatments greatly increases the risk 
of developing squamous cell carcinoma (SCC)  and PUVA treatment has therefore 
declined over the past few years. However, no risk of developing skin cancer has been 
seen with bath-PUVA treatment45. 
Climate therapy  
     Sun exposure has an immunomodulating effect with local and systemic reduction 
of T cells and cytokines46. Climatotherapy is the oldest form of phototherapy.  
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Grenz rays  
    The exact mechanism of action of Grenz rays (Bucky) is unknown but it has effects 
on the Langerhans cells in the epidermis. Grenz rays have wavelengths of around 20 
nm, lying between x-rays and ultraviolet rays. Grenz rays are used mainly for scalp 
psoriasis, but also for psoriasis in the intertriginous areas and for hand and foot 
psoriasis. Side effects are erythema and hyperpigmentation. One concern is skin 
malignancy, but the risk is considered to be low if the cumulative dose is less than 
100 Gray47.  
Traditional systemic treatment 
 Methotrexate  
     Methotrexate is a synthetic folic acid analogue with anti-proliferative and anti-
inflammatory properties. Polyglutamate, which is the primary metabolite in 
methotrexate, competitively inhibits dihyrofolate reductase, preventing the reduction 
of folate cofactors. This results in preventing pyrimidine and purine synthesis and 
DNA methylation. Methotrexate empties the intracellular stores of activated folate. 
Cell replication is disrupted and this leads to the inhibition of epidermal cell 
proliferation. At low doses, methotrexate has potent anti-inflammatory actions that 
appear to be mediated via pathways that are separate from folate antagonism. The 
inhibition of polyamines is thought to contribute to its anti-inflammatory effects. 
Methotrexate is the first line treatment for moderate to severe psoriasis when systemic 
treatment is needed. Methotrexate can be administered orally, subcutaneously or 
intramuscularly. Two different dosage regimes have been proposed. A single, once-
weekly dose and a triple dosage schedule given at 12-hours intervals, with the latter 
regimen based upon cell cycle kinetic studies48.   
 
                                              INTRODUCTION 
 
DEPARTMENT OF PHARMACOGNOSY, MMC. Page 23 
 
 Ciclosporin   
 Ciclosporin is a cyclic polypeptide consisting of eleven amino acids. It suppresses the 
activation of the calcium-dependent phosphatase calcineurin, inhibiting lymphokine 
secretion (e.g.,IL-2, IFN- Ȗ, GM-CSF, IL-3, IL-4, TNF-α and IL-17) which leads to 
diminished activation of T lymphocytes. Ciclosporin also inhibits antigen presenting 
cells. Ciclosporin is used for severe psoriasis. In recent years, the use has diminished 
since the introduction of biologic therapies. However, it does still have its place when 
there is a need for a rapid effect. Ciclosporin is nephrotoxic and functional kidney 
damage can occur quickly after treatment has started. With intermittent treatments, 
the kidney function can be normalised between treatment periods. The risk of 
irreversible kidney damage increases during long-term treatment (more than two 
years) or ciclosporin doses of >5 mg/kg per day Hypertension is another side effect, 
but is reversible after reducing the dose or after starting antihypertensive treatment. 
Ciclosporin treated patients who were previously given high doses of UV and 
especially PUVA, are at greater risk of developing skin malignancy, especially SCC49.  
  
Acitretin  
  Acitretin is a retinoid (synthetic vitamin A derivate) and has antiproliferative and 
immunomodulatory properties. In the epidermis, acitretin reduces the proliferative 
activity and favours the differentiation of epidermal keratinocytes. Acitretin inhibits 
the induction of Th17 cells and promotes the differentiation of T-regulatory cells.  
Acitretin is used for plaque psoriasis (especially in combination with UVB and 
PUVA) and also for pustulous psoriasis, hyperkeratotic hand- and foot psoriasis and 
erythrodermia. Side effects are mainly hyperlipidemia and elevated liver enzymes50.  
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 Biologics  
    Biologics are drugs derived from living material and that interfere with the immune 
system. Biologic therapies for psoriasis were introduced in Sweden in 2004. They are 
used for the treatment of moderate to severe psoriasis when traditional systemic 
therapies are contraindicated or cannot be used due to side effects or have not led to 
satisfactory treatment result51. There is a greater risk of developing serious infections 
during treatment, and screening for tuberculosis and hepatitis is mandatory before 
treatment starts. To date, there is no robust evidence of an increase in the risk of 
malignancy, but a possible future risk of lymphoma or other malignancies cannot be 
ruled out.  
 Etanercept  
    Etanercept is a human soluble TNF receptor fusion protein, binding free circulating 
TNF-α which competitively blocks TNF-α to bind to TNF-receptors. It is 
administered through subcutaneous injections52.   
Adalimumab  
   Adalimumab is a fully human anti TNF- α monoclonal antibody and it is 
administered through subcutaneous injections53.   
 Infliximab  
Infliximab is a chimeric human-mouse antibody that binds to both soluble TNFα and 
TNFα on the cell wall and is administered through intravenous infusions54.  
Ustekinumab  
     Ustekinumab is a human monoclonal antibody that binds with high affinity and 
specificity to the p40 protein subunit that is used by both the interleukin (IL)-12 and 
the IL-23 cytokines. It is administered through subcutaneous injections55  
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Ayurvedic drug treated in psoriasis  
     Herbs may be used In  the treatment of psoriasis in different formulations like 
dried extracts ,tinctures, decoctions, topical cream, gel, ointment and oral 
formulations like tablets. these herbs have potent activity against psoriasis 
inflammation similar to allopathic drugs with minimum or no side effects even on 
long term use. 
The following are some of the herbs used for the treatment of psoriasis are as 
follows56
  1.silybum marianum 
  2.rumex crispus 
  3.trifolium pretense 
  4.smilax sarsaparilla 
  5.coleus forskohli 
  6.stellaria medica  
  7.calendula officinalis 
  8.astragalus memranaceus 
  9.thespesia populnea   
 10.momordica charanta 
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                        3. AIM AND OBJECTIVES 
           Indigofera aspalathoides plant are used in the treatment of  skin disease in 
ethanomedicine. The literature  survey  indicates that no scientific data on the anti 
psoriatic  activity of this plant. 
Various  parts  of these plants have been claimed to be effective in a wide range  of 
disease .The scientifically state  therapeutic properties for Indigofera aspalathoides have 
reported antimicrobial, anti-inflammatory, anticancerous, anti-oxidant, hypoglycemic, 
hepatoprotective,  antiviral, Antitumor activity Antidiabetic ,Wound Healing64-71 . 
Rationale of the study 
    The allopathic drugs like methotrexate, corticosteroids and immuno suppressant  
shows effective response in psoriasis by reducing  the scale ,plaque ,cell proliferation and 
inflammation  but  the adverse reaction  is severe than the efficacy  of the drug .the long 
term usage of drug causes serious  adverse  reaction like hepatotoxicity, renal failure 
sometimes leads to fatality.So  the herbal drugs are safe in psoriasis treatment  since  the 
adverse effect is mild or nil and lower the cost of therapy as comparable to the allopathic 
medicine. 
The present investigation  was therefore  proposed to: 
1. To evaluate  the  anti-microbial activity related  to  psoriasis from the different extract 
of  whole plant of  Indigofera aspalathoides. 
2. To formulate herbal  ointment  with different extract of whole plant of  indigofera 
aspalathoides. 
3. To evaluate the formulated  herbal ointment 
4. To evaluate the anti-psoriatic activity  of  ointment  by  mice skin test. 
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                 4.   ETHNOBOTANICAL   SURVEY    
 
4.1 PLANT  PROFILE 
  Plant name: Indigofera aspalathoides vahl ex dc 
  Tamil name  : Iraivan vembu, shivanar vembu 
   Family  : Fabaceae 
4.2 VERNACULAR NAMES:73,74 
 English name :  Shiva ‘s name , wiry indigo      
 Kannada  : shivamalli-gida, neelamalligida 
Malayalam : manali 
Sanskrit  : ratakohomba, sivanimba 
Sinhalese : ratkohomba 
Marathi : Shiva nimb 
Punjabi  : mil 
 
4.3 TAXANOMY CLASSIFICATION: 
Kingdom: Plantae 
Order  : Fabales 
Family  : Fabaceae 
Subfamily: Faboideae 
Tribe : Indigofereae 
Genus  : Indigofera.L 
species  : Indigofera aspalathoides vahl 
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4.4 DISTRIBUTION 
india , deccan plains of Carnatic and ceylon . 
 
4.5  HABITAT 
    A low much  branched erect under shrub,branches rigid, divaricately spreading. 
 
4.6 BOTANICAL CHARACTERS:75 
   Leaves            : 1-5 foliolate, digitate, sessile, croweded on the young           
     branches but soon decideous stipules  minute subulate. 
  Flowers           : solitary,  axillary ,corolla red or dark pink,exserted. 
  Pedicles           : 1/8-1/4 inch , filiform. 
  Leaflets            :2.5-6mm long , 1mm wide pale green in colour  ,linear,apiculate. 
  Calyx               : 1.5mm long ,incised more than half way . 
  Pods                : 1.2-1.5cm long, straight, glabrous with a few scattered  hairs.  
  Stem                : dark brown, branched 0.7 to3.0 cm 
  Root                 : brown colour, woody, lateral roots present 0.5 to 3.0 cm width  
 4.6 PLANT CHEMICALS:76 
 
                            Alkaloids 
                            flavonoids 
                           carbohydrate 
                           phenolic compound 
                           saponins 
                           steroids 
                           tannins 
                           β-sitosterol 
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4.7 ETNOMEDICAL  INFORMATION:77,78 
  1. Leaves, flowers, and tender shoots  : cooling demulcent, employed in decoction,     
      leprosy and cancerous affections. 
 2. Whole plant  : oedematous tumours. 
 3. Leaves : applied to abscesses.  
 4. Root  : chewed as a remedy for toothache  and apthae of the mouth.  
 5. Decoction of entire plant : given as an alternative in secondary syphilis, 
      psoriasis etc.   
  6. Oil  from root  : used to anoint the head in  erysipelas and skin diseases. 
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                        5.   PLAN OF WORK 
 
1. COLLECTION OF PLANT MATERIAL 
2. AUTHENTICATION 
3. PHARMACOGNOSTICAL STUDIES 
                                        MACROSCOPY 
                                        MICROSCOPY 
 Histochemical studies 
 Powder microscopy 
 Quantitative microscopy – Linear measurement 
 Physiochemical constants 
 
4. PHYTOCHEMICAL STUDIES 
 
 Preparation of extracts 
 Preliminary phytochemical analysis 
 Quantitative estimation of phytoconstituents 
 Fluorescence analysis 
 Thin layer chromatography 
 High performance thin layer chromatography 
              5. IN -VITRO STUDIES 
                                              1. Anti-oxidant activity 
        2. Anti- microbial activity 
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            6.  FORMULATION AND EVALUATION OF HERBAL OINTMENT 
 Formulation  and evaluation of herbal ointment of extracts of whole plant of   
Indigofera aspalathoides  
1. Physical Examination 
2. Determination of pH 
3. Extrudability: 
4. Spreadability 
5. Skin sensitivity test 
 
        7. IN-VIVO ANTI- PSORIASIS ACTIVITY 
                Evaluation  of  anti-psoriatic  activity  with extract  of  whole plant  of 
Indigofera aspalathoides herbal  ointment  by  mice skin test. 
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             6. PHARMACOGNOSTICAL STUDIES 
  6.1 MATERIAL AND METHODS 
  COLLECTION  OF  PLANT MATERIAL 
     The whole plant of Indigofera aspalathoides was collected in 2016 July at  
panakudi village ,tirunelveli district , tiruneveli -627011. 
 AUTHENTICATION  
        The collected specimens was botanically identified and authenticated by         
 V. Chelladurai, Research Officer-Botany (Scientist) , Central Council for Research   
in Ayurveda and Siddha , Govt Of India, tiruneveli -627011. 
MACROSCOPIC  EVALUATION 
  The morphological feature of  the  plant  was evaluated and recored. 
MICROSCOPIC  EVALUATION 79-82 
 
 Fixation of leaf, stem and root 
 The whole plant was cut and fixed in FAA solution (Formalin 5ml + Acetic acid  
5ml +  90ml of 70% Ethanol). The specimen was dehydrated after 24 hours of 
fixing. The whole plant was graded with series of tertiary butyl alcohol, as per the 
standard procedure. 
  It was carried out by gradual addition of 58 – 60º C of melting pointed paraffin 
wax until Tertiary butyl alcohol (TBA) solution attained super saturation. The 
specimens were cast into paraffin blocks. 
The paraffin embedded specimens were sectioned with the help of Rotary 
Microtome. The thickness of the sections was 10 - 12µ. De-waxing of the sections  
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was done by customary procedures. The sections were stained with haematoxilin. 
The stained sections were viewed under microscope. 
 
POWDER MICROSCOPY83,84 
 The shade dried whole plant was powdered and used for powder microscopic 
analysis. The organoleptic characters were observed and to identify the different 
microscopical characteristic features various staining reagent were used. Powder 
was stained with 1% phloroglucinol in 90% ethanol, concentrated hydrochloric acid 
and observed under microscope. Powder analysis is used for the detection of 
characteristic structures and various cell components. 
QUANTITATIVE MICROSCOPY85 
LINEAR MEASURMENT OF FIBRES  
The length and width of the fibers present in the whole plant were observed under 
microscope. This quantitative analysis will be helpful in the identification of the  
drug.The first step involved in this is calibration of the eyepiece micrometer using 
the stage micrometer. For determining the calibration factor, the eyepiece is 
removed from the microscope, then the lens is unscrewed and in the ridge the 
eyepieces micrometer is placed. The lens is then replaced. The stage micrometer is 
then placed on the stage of the microscope and focused under high power with the 
eyepiece coincides with each division of stage micrometer and calculate the 
calibration factor using the standard formula. The stage micrometer is replaced with 
the slide containing the powdered drug. The slide is prepared by using the whole 
plant powder on a slide is treated with a drop of phloroglucinol and conc. 
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Hydrochloric acid and viewed under microscope. The width and length of fibers is 
measured by focusing them on the lines of the eyepiece micrometer. Note the no. of 
divisions covered by the length and width of the fibers. 
PHYSIOCHEMICAL ANALYSIS86,87 
The shade dried powdered whole of Indigofera aspalathoides, was used for the 
analysis of various physiochemical parameters which is useful in the determination 
of quality and purity of crude drugs. Total ash, extractive values, loss on drying, 
foaming index, swelling index and foreign organic matters were determined as per 
the standard WHO guidelines which is very much useful in the determination of 
quality and purity of the crude drugs. 
  
DETERMINATION OF  ASH  VALUES 
The residue remaining after incineration is the ash content of the drug, which simply 
represents the inorganic salts naturally occurring in the drug or adhering to it or 
deliberately added to it as a form of adulteration. 
TOTAL ASH 
Silica crucible was heated to red hot for 30 minutes and it was allowed to cool in 
desiccators. About 2gm of powdered sample was weighed accurately and evenly 
distributed in the crucible. Dried at 100 – 105ºC for 1 hour and ignited to constant 
weight in a muffle furnace at 600±25ºC. The crucible was allowed to cool in a 
desiccator. The percentage yield of ash with reference to the air dried substance was 
then calculated by the formula 
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 Water soluble ash 
The total ash was boiled for 5min with 25ml of water. The insoluble matter was then 
collected in an ash less filter paper. It was washed with hot water and ignited for 
15min at a temperature not exceeding 450ºC. The weight of the insoluble matter was 
subtracted from the weight of the ash and the difference in weight represented the 
water soluble ash, the percentage of water soluble ash with reference to the air dried 
substances was calculated with reference to the air dried material. 
 Acid insoluble ash 
Acid insoluble ash is the residue obtained after boiling the total ash with dilute 
hydrochloric acid, and igniting the remaining insoluble matter. This measures the 
amount of silica present, especially as sand and siliceous earth 
Procedure 
To the total ash obtained previously, 25ml of dilute hydrochloric acid was added, 
covered with a watch glass and boiled gently for 5min on a burner. The watch glass 
was rinsed with 5ml of hot water and these washings were added to the crucible. 
The insoluble matter was collected on an ash less filter paper by filtration and the 
filter paper was rinsed repeatedly with hot water until the filtrate is neutral and free 
from acid. Filter paper containing the insoluble matter was transferred to the 
crucible, dried on a hot plate and ignited to a constant weight in the muffle furnace 
at 450- 500ºC. The silica crucible was removed from the muffle furnace and 
allowed to cool in a desiccator for 30min, and then weighed without delay. The 
content of acid insoluble ash was calculated. 
PHARMACOGNOSTICAL STUDIES 
 
DEPARMENT OF PHARMACOGNOSY, MMC. Page 38 
 
 
Sulphated ash 
About 3gm of air-dried substance was ignited gently at first in a crucible, until the 
substance was thoroughly charred. Then the residue was cooled, moistened with 
1ml of  sulphuric acid, heated gently until the white fumes were no longer evolved  
and ignited at 800 ± 25ºC, until all the black particles were disappeared. The 
crucible was allowed to cool, a few drops of sulphuric acid was added and heated. 
Then it was ignited as before, cooled and weighed.  
The percentage of sulphated ash with reference to the air- dried substance was then 
calculated. 
 
DETERMINATION OF EXTRACTIVE VALUES 
This method is used to determine the amount of active constituents in a given 
amount of plant material when extracted with solvents. Extractive values are useful 
for the evaluation of phytoconstituents especially when the constituents of a 
drug cannot be readily estimated by any other means. Further these values indicate 
the nature of the active constituents present in a crude drug. 
Determination of water soluble extractive 
About 5gm of the powder was weighed and macerated with 100ml of chloroform 
water (95ml distilled water and 5ml chloroform) in a closed flask for 24 hours. It 
was shaken frequently for six hours and allowed to stand for eighteen hours. It was 
then filtered rapidly, taking precautions against loss of solvent and 25ml of the 
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filtrate was evaporated to dryness in a tarred flat bottomed shallow dish. 2 ml of 
alcohol was added to the residue and it was dried at 105ºCfor 1 hour in the hot air 
oven and cooled in desiccators for 30min and weighed. The process was repeated 
till a constant weight was obtained; the percentage of water soluble extractive value 
with reference to the air dried drug was calculated. 
Determination of  alcohol soluble extractive 
The alcohol soluble extractive value is also indicative for the same purpose as water 
soluble extractive value. The solvent strength of alcohol varies from 20- 90%v/v. 
The solvent strength has to be chosen depending upon the strength of alcohol used 
for the extraction of powdered drug. 
Procedure 
About 5gm of the powder was weighed and macerated with 100ml 90% ethanol in a 
closed flask for 24 hours. It was shaken frequently for six hours and allowed to 
stand for eighteen hours. It was then filtered rapidly, taking precautions against loss 
of solvent and 25ml of the filtrate was evaporated to dryness in a tarred flat 
bottomed shallow dish. It was dried at 105ºC for 1hour in a hot air oven. The dish 
was cooled in desiccator and weighed. The process was repeated till the constant 
weight was obtained. The percentage of alcohol soluble extractive value with 
reference to the air dried drug was calculated. 
LOSS ON DRYING 
Accurately weighed quantity of the substances was taken in a previously ignited and 
cooled silica crucible and the substance was evenly distributed by gentle side wise 
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substance was heated for a specified period of time to a constant weight. The 
crucible was covered with the lid and allowed to cool in a desiccator at room 
temperature before weighing. Finally the crucible was weighed to calculate the loss 
on drying with reference to the air dried substance. 
 
DETERMINATION OF FOAMING INDEX 
About 1gm of the coarsely powdered drug was weighed and transferred to 500ml 
conical flask containing 100ml boiling water. The flask was maintained at 
temperature 80-90ºC for about 30min. It was then cooled and filtered into a  
volumetric flask and sufficient water was added through the filtrate to make up the 
volume to 100ml. The decoction was poured into 10 stopper test tube (height 16cm, 
diameter 16mm) in successive portions of 1ml, 2ml, 3ml, 4ml up to 10ml and the 
volume of the liquid in each tube was adjusted with water to 10ml. The tubes 
were stoppered and shaked in a length wise motion for 15 seconds, two shakes per 
second. Allowed to stand for 15min and the height of the foam were measured. The 
results are assessed as follows: if the height of the foam in every tube is less than 
1cm, the foaming index is less than 100. If  a height of 1cm is measured in any tube, 
the  volume of the plant material decoction in the tube (a) is used to determine the 
index.  If this tube is the first or second tube in a series, prepare an intermediate 
dilution in a similar manner to obtain a more precise result. The height of the foam 
is more than 1cm in every tube the foaming index is over 1000. In this case repeat 
the  determination using a new series of dilution of the decoction in order to obtain a 
result. Calculate the foaming index using the following formula. 
 
PHARMACOGNOSTICAL STUDIES 
 
DEPARMENT OF PHARMACOGNOSY, MMC. Page 41 
 
Foaming index = 1000/a  
 
Where, a is the volume in ml of the decoction used for preparing the dilution in 
the tube where foaming to a height of 1cm is observed. 
DETERMINATION OF SWELLING INDEX 
The swelling index is the volume in ml occupied by the swelling of 1gm of plant 
material under specified conditions. 
Procedure 
A specified quantity of the plant material was accurately weighed and transferred into 
a 25ml glass stoppered measuring cylinder. The internal diameter of the cylinder 
should be about 16mm, the length of the graduated portion about 125mm, marked in 
0.2ml divisions from 0 to 25ml in an upward direction. Unless otherwise indicated in 
the test procedure, add 25ml of water and shake the mixture thoroughly every 10min 
for 1hour, allowed to stand for 3 hours at room temperature. The volume in ml 
occupied by the plant material was measured including any sticky mucilage. Calculate 
the mean value of the individual determination, related to 1gm of plant material
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.                 6.2 RESULTS AND DISCUSSION 
The results of pharmacognostical studies are as follows. 
ORGANOLEPTIC CHARACTER 
   Leaf           –   pale green 
   Stem          –   dark brown 
    Root         –    brown colour  
MICROSCOPY OF LEAFLET, STEM AND ROOT 
T.S. OF LEAFLET  
The leaflet is either flat or folded adaxially forming V Shaped outline. The midrib part 
is 170μm thick vertically and 200μm horizontally. The epidermis along the adaxial 
groove is smooth and has rectangular cells. The xylem elements are narrow, angular, 
thick walled and compact. The leaf margin is slightly dilated and it is semicircular in 
sectional view with 130μm thick. The epidermal layer of the leaf margin is thick . The 
mesophyll tissue is differentiated into palisade and spongy parenchyma similar to the 
middle part of the leaflet.  AdS: Adaxial side,  PM – Palisade Mesophyll, SM- 
Spongy Mesophyl   
    
                                       FIG:14     T.S. OF LEAFLET 
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 T.S. OF STEM 
The stem is circular in sectional view with smooth and even surfaces with 900 μm 
thick. The epidermal cells are 5 μm thick. The cortical zone is 100 μm wide. It is 
heterogeneous comprising of outer part of four or five layers of small compact cells, 
in addition to wide isolated group of two or three cells; the middle part has prominent, 
discrete, circular masses of gelatinous or mucilage fibres, arranged in a ring, all 
around the stem . The inner cortex has four or five layers of fairly wide, compact 
parenchyma cells of varying dimensions. Phloem occurs in continuous sheath 
encircling the xylem. The vessel lines extend from the inner to outer boundaries of the 
cylinder. 
 
                              FIG :15 T.S  OF STEM  
  Ep - Epidermis,  
 Co – Cortex, Ph – Phloem, X: Xylem, Pi: Pith. 
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T.S. OF ROOT 
  The thin root consists of four or five layers of tubular, suberized phloem cells. 
Secondary phloem consists of outer dark cylinder of crushed phloem and 
sclerenchyma elements. inner phloem has non collapsed, radial files of elements 
without sclerenchyma cells. Secondary xylem is circular. The wide vessel in the outer 
zone is 50 μm in diameter. Secondary phloem is differentiated into outer collapsed 
phloem and inner non collapsed phloem. The collapsed phloem is much wider and 
consists of funnel shaped dilated rays alternating with triangular cones of fibres and 
crushed phloem elements. The fibres are gelatinous type; they have inner gelatinous 
unlignified walls and outer lignified walls.  
                
                                    FIG:16   T.S OF ROOT    
             Ph – Phloem, X: Xylem, PE:Periderm, 
             Ph F – Phloem Fibre, XF – Xylem fibre, Ve – Vessel. 
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POWDER MICROSCOPY                    
 Powder microscopy revealed the presence of the following structures 
 1. Epidermal cells: These cells were present in outer region; the walls may be straight 
and brownish in colour. 
2. Non-lignified fibre: They were present in mid rib region (sclerenchyma region). 
They are thin walled narrow lumen, and pointed ends. 
3. Trichomes: Two types of trichomes were present. (A) Uni cellular covering 
trichomes: they were found to be long, slender and bent at the base and pointed apex. 
(B) Knee shaped trichomes: they were present at lamina region, these types of 
trichome are also present in vasaka leafs. 
4. Xylem vessels : spiral 
5. Calcium oxalate : prism of calium oxalate 
                                FIG:17  POWDER CHARACTERS       
 
Epidermal cell                         Non-lignified fibre                 Unicellularcovering       
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     Knee- shaped trichomes          Calcium oxalate crystals    Xylem vessels 
 
 Spiral nature xylem vessels          Collenchymas cells                       Stone cells 
QUANTITATIVE MICROSCOPY 
Linear measurement of fibres 
The length and width of the fibres were measured in the powdered whole plant of 
Indigofera aspalathoides and the results were shown in  table no: 1 
PARAMETERS MINIMUM (µm) AVERAGE (µm) MAXIMUM (µm) 
Length 87 205 420 
Width 3.5 8.27 11.38 
The length of the fibers were in the range of 87µ m - 420 µ m and the width of the 
fibers was found in the range of 3.5 µ m – 11.38 µ m. 
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PHYSIOCEMICAL PARAMETERS  
Physiochemical constants like total ash values, acid insoluble ash, water soluble ash, 
extractive values, loss on drying, swelling index, foaming index were studied and 
reported in table no: 2 
        Table no: 2 Physiochemical parameters of  Indigofera aspalathoides whole plant 
S.NO PARAMETERS 
 
VALUES (%W/W) 
1. Total ash 11.5±0.56 
2. Acid insoluble ash 8.0±0.25 
3. Water soluble ash 9.3±0.45 
4. Sulphated ash 4.2±0.65 
 EXTRACTIVE VALUE  
5.  Alcohol soluble extractive 7.3±0.26 
6. Water soluble extract 6.9±0.12 
7. Loss on drying 12.6±0.74 
8. Foaming index Nil 
9. Swelling index Nil 
 
The total ash, acid insoluble ash, water soluble ash and sulphated ash were 
found to be11.5±0.56, 8.0±0.25% w/w, 9.3±0.45% w/w, 4.26±0.65% w/w 
respectively. The water soluble extractive, alcohol soluble extractive values 
were found to be   6.9±0.12% w/w, 7.3±0.26% w/w, respectively. Loss on 
drying was found to be 12.06±0.74% w/w. The foaming index and swelling 
index was found to be nil. 
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This detailed Pharmacognostical investigation on the whole plant of Indigofera 
aspalathoides  will be useful for the identification of the drug in crude as well 
as powder form in order to differentiate the plant from its allied species and 
adulterants. 
 
 
 
 
 
  
 
 
 
 
 
 
 
                      7.  PHYTOCHEMICAL STUDIES 
 
7.1 MATERIAL AND METHODS 
Phytochemical evaluation is used to determine the nature of phytoconstituents 
present in the plant by using suitable chemical tests. Phytochemical analysis is very 
much important because the therapeutic activity is based on the constituent present 
in the drug. It can be done by confirmation with different chromatographic 
techniques like TLC and HPTLC. Therefore a complete investigation is required to 
characterize the Phytoconstituents qualitatively and quantitatively. 
PREPARATION OF EXTRACTS 
Whole plant was collected, dried in shade, coarsely powdered and successively 
extracted with solvents of increasing polarity like chloroform, ethyl acetate and 
ethanol by continuous percolation process using soxhlet apparatus. After extraction 
each extracts were concentrated by using rotary vacuum evaporator. It is dried and 
the percentage yield was calculated. Appearance and consistency of the extract were 
also noted.  
PRELIMINARY  PHYTOCHEMICAL  SCREENING88,89 
The whole plant powder and extracts were subjected to qualitative chemical analysis 
for the identification of active constituents in each extracts and the powdered  whole 
plant. 
 
 DETECTION OF ALKALOIDS 
Dragendorff’s reagent 
To the sample 5ml of 2M HCl was added. Then 1ml of Dragendorff’s reagent was 
added and examined for an immediate formation of an orange red precipitate.     
Mayer’s reagent 
To the substance little quantity of dilute hydrochloric acid and Mayer’s  reagent 
were added and examined for the formation of white precipitate. 
Wagner’s reagent 
The test substance was treated with little amount of Wagner’s reagent and examined 
for   the formation of reddish brown precipitate. 
DETECTION OF GLYCOSIDES 
Borntrager’s test 
The powdered material was boiled with 1ml of sulphuric acid in a test tube for five 
minutes. Filtered while hot, cooled and shaken with equal volume of chloroform. 
The lower layer of solvent was separated and shaken with half of its volume of 
dilute ammonia. A rose pink to red colour is produced in the ammonical layer 
indicates the presence of anthroquinone glycosides. 
Modified Borntrager’s test 
The test material was boiled with 2ml of the dilute sulphuric acid. This was treated 
with 2ml of 5% aqueous ferric chloride solution (freshly prepared) for 5 minutes, 
and shaken with equal volume of chloroform. The lower layer of solvent was 
separated and shaken with half of its volume of dilute ammonia. A rose pink to red 
colour is produced in the ammonical layer. 
Legal’s test 
The test sample when treated with sodium nitropruside in pyridine and methanolic 
alkali. Formation of a pink red colour indicates the presence of cardiac glycosides. 
DETECTION OF STEROIDS AND TRITERPENOIDS 
LibermannBurchards Test 
The powdered drug was treated with few drops of acetic anhydride, boiled and 
cooled. Conc.sulphuric acid was added from the sides of the test tube formation of 
brown ring is formed at the junction of two layers and upper layer turns green which 
shows presence of steroids and formation of deep red color indicates presence of tri 
terpenoids. 
Salkowski Test 
The extract was treated with few drops of concentrated sulphuric acid, red color at 
lower layer indicates presence of steroids and formation of yellow colored lower 
layer indicates presence of tri terpenoids. 
DETECTION OF FLAVONOIDS 
Shinoda’s test 
Small quantity of extract was dissolved in alcohol to this pieces to magnesium 
followed by concentrated hydrochloric acid were added drop wise and heated. 
Appearance of magenta colour shows the presence of flavonoids. 
Alkaline reagent test 
Small quantity of the extract was dissolved in aqueous sodium hydroxide and 
appearance of yellow colour indicates the presence of flavonoids. 
DETECTION OF CARBOHYDRATES 
Molisch’s test 
To the test solution few drops of alcoholic alpha napthol and few drops of conc. 
sulphuric acid were added through the sides of test tube, purple to violet color ring 
appears at the junction indicates the presence of carbohydrates. 
Fehling’s test 
The test solution was mixed with Fehling’s I and II, heated and examined for the 
appearance of red coloration for the presence of sugar. 
DETECTION OF TANNINS 
Lead acetate test 
The test solution was mixed with basic lead acetate solution and examined for 
formation of a white precipitate. 
Ferric chloride test 
A few drops of 5% aqueous ferric chloride solution was added to 2ml of an aqueous 
extract of the drug and examined for the appearance of bluish black color. 
 
 
 
DETECTION OF PROTEINS 
Biuret test 
The sample was treated with 5-8 drops of 10% w/w copper sulphate solution and 
observed for the presence of violet color. 
 
DETECTION OF SAPONINS 
A drop of sodium bicarbonate solution was added to the sample and the mixture was 
shaken vigorously and left for 3 minutes. Development of any honey comb like 
froth was examined. 
DECTECTION OF GUMS AND MUCILAGE 
The small quantities of test substance were dissolved in 5 to 10ml of acetic 
anhydride by means of heat, cooled and added 0.05ml of conc. sulphuric acid. 
Formation of bright purplish red color indicates the presence of gums and mucilage. 
DETECTION OF FIXED OILS AND FATS 
Small quantities of extracts were pressed between two filter papers. An oily stain on 
the filter paper indicates the presence of fixed oils and fats. 
QUANTITATIVE ESTIMATION OF  TOTAL FLAVONOID CONTENT90  
Total Flavanoid content 
Total flavanoid content was determined by calorimetric method, using quercetin as a 
standard. The test samples were individually dissolved in DMSO. Then the sample 
solution (150 µl) was mixed with 150 µl of 2% aluminium chloride. After 10min of 
incubation at ambient temperature, the absorbance of the supernatant was measured at 
435nm using spectrophotometer. Three replicates were made for each test sample. 
The total flavanoid content was expressed as quercetin equivalent in mg/gm extract 
(mg QRT/gm extract). 
 
FLUORESCENCE  ANALYSIS91,92 
Many crude drug show Fluorescence when the sample is exposed to UV radiation. 
Evaluation of crude drugs based on fluorescence in day light is not much used, as it 
is usually unreliable due to the weakness of the fluorescent effect. Fluorescent lamps 
are fitted with suitable filter, which eliminate visible radiation from the lamp and 
transmits UV radiation of definite wavelength was used for the study several crude 
drugs show characteristic fluorescence which is very much useful for their 
evaluation. 
THIN LAYER CHROMATOGRAPHY93 
Principle 
The principle of separation is adsorption. It is reliable technique in which solute 
undergoes distribution between two phases, stationary and mobile phase. The 
mobile phase flows through because of capillary action (against gravitational force). 
The compounds having higher affinities towards the stationary phase eluted slower 
were as the compound having lesser affinities towards stationary phase eluted faster. 
TLC Plate Preparation 
The plates were prepared using Stahl TLC spreader. 40gm of silica gel G was mixed 
with 85ml of water to prepare homogenous suspension and poured in the spreader. 
0.25mm thickness of plates was prepared, air dried until the transparency of the 
layer disappeared, then dried at 110ºC for 30 minutes and kept in desiccators. 
Selection of mobile phase 
Solvent mixture was selected on the basis of the phytoconstituents present in each 
extract. Factors such as nature of components, stationary phase, polarity, influence 
the rate of separation of constituents was considered. From the vast analysis, best 
solvents were selected which showed good separation with maximum number of 
components. 
 
                                Distance travelled by solute from the baseline 
      Rf value=              
                                Distance travelled by solvent from the baseline 
 
 
HPTLC- FINGER PRINT PROFILE94 
HPTLC is one of the versatile chromatographic method which helps in the 
identification of compounds and thereby authentication of purity of herbal drugs. The 
time required in this method for the demonstration of most of the characteristic 
constituents of a drug is very quick and short. In addition to qualitative detection, 
HPTLC also provides semi- quantitative information on major active constituents of a 
drug, thus enabling an assessment of drug quality. 
  
Instrument Conditions 
Sample used              : Ethanol Extract 
Instrument                : CAMAG HPTLC 
HPTLC Applicator  : CAMAG LINOMAT IV 
HPTLC Scanner      : CAMAG TLC SCANNER II 
Sample dilution        : 100mg of sample extracted with 1ml of Ethanol 
Volume of injection  : 20μl 
Mobile phase             : Hexane: Ethyl acetate: Chloroform: Methanol: Formic acid 
                                    (2:3:5:0.5:0.5)  
Lambda max            : 400 - 800nm 
Lamp                        : Tungsten 
Stationary phase      : TLC Aluminium coated silica gel 60 F254 (Merck) 
Equipment               : A Camag HPTLC system equipped with a sample applicator 
                         Linomat IV, Twin trough plate development chamber, TLCScanner II.
  
  
Chromatographic conditions 
The estimation has been done using the following chromatographic 
conditions.Chromatography was performed on a 12 × 3 cm (H x W) pre-activated 
HPTLC silicagel 60 F254 plate. Samples were applied to the plate as 6mm wide band 
with an automatic TLC applicator Linomat IV with nitrogen flow (CAMAG, 
Switzerland), 8mm from the bottom. Densitometric scanning was performed on 
CAMAG scanner II. The plates were prewashed with solvent ethyl acetate. HPTLC 
serves as a convenient tool for finding the distribution pattern of phytoconstituents 
which is unique to each plant. The fingerprint obtained is suitable for monitoring the 
identity and purity of drugs and for detecting adulteration and substitution. HPTLC 
technique is helpful in order to check the identity, purity and standardize the quantity 
of active principles present in the herbal extract. 
 
 
       
         7.2RESULTS AND DISCUSSION 
 
 Phytochemical investigations were carried and the results are as  follows. 
 Table no: 3 Percentage yield  extracts of  Whole plant   of 
indigofera aspalathoides., 
  
S.NO EXTRACT YIELD (%W/W) 
1. Chloroform 6.8 
2. Ethyl acetate 6.2 
3. Ethanol 7.6 
 
QUALITATIVE PHYTOCHEMICAL ANALYSIS 
 
 
 
TABLE NO: 4 PRELIMINARY PHYTOCHEMICAL ANALYSIS 
 
 
Note : +  - Indicates the presence and absence 
 
From the qualitative analysis, it was observed that the ethanol extract showed the presence of 
maximum active constituents such as flavonoids, steroids, carbohydrate,  and alkaloids. All 
these compounds were found in the powdered whole plant also. The ethyl acetate extract also 
showed the presence of more number of active constituents. Chloroform extract showed the 
S.
N 
CHEMICAL 
CONSTITUENS 
 
POWDERED 
DRUG 
CHLORO 
FORM 
ETHYL 
ACETATE 
ETHANO
L 
1 Flavanoids + + + + 
2 Alkaloids + + - + 
3 Carbohydrates + + + + 
5 Proteins & Amino 
acids 
- - - - 
6 Fats and fixed oils + + - + 
7 Steroids + + + + 
8 Glycosides + + - - 
9 Carbohydrates + + + + 
10 Gums & Mucilage - - - - 
11 Phenols - - + - 
12 Saponins - - - - 
13 Volitle oils - - - - 
presence of glycoside, fat and fixed oil and alkaloids. All extract showed the presence of 
steroids and flavonoids 
 
TOTAL FLAVONOID CONTENT 
Total flavonoid content was determined and compared with that of standard and thus 
ethanolic extract was found to have higher absorbance than ethyl acetate. It is represented in 
table 
                        Table No :5  Determination of Total Flavanoid Content 
S.No Concentration of standard 
solution(µg/ml) 
Absorbance(765nm) 
1. 2 0.06 
2. 4 0.10 
3. 6 0.13 
4. 8 0.16 
5. 10 0.21 
6. Ethyl Acetate 0.14 
7. Ethanol 0.16 
 
Standard calibration curve for determination of Total Flavonoid Content 
 
Fig : 1 Total Flavonoid content 
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FLUORESCENCE ANALYSIS 
 
TABLE NO: 6 FLUORESCENCE CHARACTERISTIC OF 
POWDEREDWhole plant OF indigofera aspalathoides 
  
S.NO TREATMENT DAY LIGHT SHORT-UV 
(254nm) 
LONG-
UV(365nm) 
1 Powder Pale brown  Black  Brown 
2 Powder + Water White viscus Light black  Brown 
3 Powder + Ethanol   Light yellow  Brown Light brown 
4 Powder + 1N 
HCL 
Yellow Yellow Greenish brown 
5 Powder + 1N 
H2SO4 
       Black Black  Brown 
6 Powder +  1N 
NaOH 
Green  Black         Dark green  
7 Powder + 1N 
alcoholic KOH 
Dark green  Brown Dark brown 
8 Powder + FeCl3 Green             Green Light brown 
9 Powder + Acetic 
acid 
Light brown Green 
 
White viscus  
10 Powder + 
Ammonia 
Yellow  Green light brown 
11 Powder + Iodine Deep brown Brown        Pale yellow 
 
Fluorescence characteristics of the extracts of the whole plant of  Indigofera 
aspalathoides  TABLE NO: 7 
 
S.NO EXTRACTS DAY LIGHT  SHORT-UV (254nm) LONG-UV (365nm) 
1 Chloroform Brown Light brown Black 
2 Ethyl acetate Brown Dark brown Dark brown 
3 Ethanol Light brown Brown  Brown 
 
There was no characteristic fluorescence were seen with either the powdered whole 
plant or the extracts 
 
 
 
 
CHROMATOGRAPHIC STUDIES 
THIN LAYER CHROMATOGRAPHY 
 
 Thin layer chromatography was done with all the three extracts and their Rf values 
were   tabulated in the table no: 8 
 
s.no 
 
extract 
 
Solvent system 
 
No. of 
spot 
 
 
Rf value 
1 chloroform  
Chloroform : 
methanol(9:1) 
 
 
5 
 
085, 0.65 
0.57,0.52, 
0.47 
 
2 
 
Ethyl acetate 
 
Chloroform :    
methanol(9:1) 
 
 
4 
 
 
 
0.87,0.77,0.70,0.62 
3  
Ethanol 
 
Chloroform :    
methanol(9:1) 
 
 
7 
 
0.85,0.72,0.67,0.62
,0.57,0.50,0.45 
             
    
                    
    
            FIG:2   THIN LAYER CHROMATOGRAPHIC STUDIES OF EXTRACT 
 
 
 
 HPTLC FINGER PRINT PROFILE 
 
HPTLC Finger print Data of Ethanolic Extract of Indigofera aspalathoides.High 
performance thin layer chromatography (HPTLC) finger printing was performed with 
the ethanol extract of Indigofera aspalathoides The chromatographic conditions were 
carried as detailed in material and method of this study. There were 12 peaks 
observed with different Rf Values and different heights. Percentage of areas was also 
obtained from the chromatogram.  
 
FIG :3  HPTLC OF ETHANOLIC  EXTRACT 
                                          
                                                             
 FIG :4  FINGER PRINT DATA ANALYSIS FOR HPTLC 
 
                                          
 
 
       TABLE NO: 9 HPTLC FINGER PRINT DATA 
 
    
S. No Rf Height Area 
1 0.10 6.3 44.1 
2 0.11 3.3 62.3 
3 0.17 5.8 86.6 
4 0.22 4.0 80.6 
5 0.25 3.8 100.6 
6 0.33 4.6 81.9 
7 0.34 6.1 191.9 
8 0.45 1.5 24.7 
9 0.49 10.3 206.6 
10 0.54 8.6 236.2 
11 0.64 41.9 1949.5 
12 0.69 18.1 753.2 
 
 
  
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
       Selection of Active extract 
 
SELECTION OF ACTIVE EXTRACT 
 
DEPARTMENT OF PHARMACOGNOSY, MMC Page 63 
 
                8. SELECTION OF ACTIVE EXTRACT 
 
8.1 MATERIALS AND METHODS 
In order to select the best extract all the extracts were subjected to in-vitro 
antioxidant activity and anti-microbial studies. These studies are used for the 
selection of best extract which would take to precede the further activities. 
IN VITRO ANTIOXIDANT ACTIVITY
95
 
Antioxidant is a molecule that inhibits oxidation of other molecule which 
produces free radicals. These radicals in turns produce chain reactions there by 
cause damage to the cells, resulting in development of various ailments. 
Antioxidant terminates these chain reactions by removing free radicals and 
inhibiting oxidative reactions. Therefore, antioxidant with free radical 
scavenging effect will be of greater importance in the prevention and 
therapeutics of disease. 
       DPPH ASSAY (2, 2-DIPHENYL -1-PICRYLHYDRAZYL) 
Antioxidants react with DPPH and reduce it to DPPH-H and as consequence 
the absorbance decreases. The degree of discoloration indicates the scavenging 
potential of the antioxidant compounds or extracts in terms of hydrogen 
donating ability. Different volumes (1.25-10µ l) of plant extracts were made up 
to 40µ l with DMSO and 2.96ml DPPH (0.1mM) solution was added. The 
reaction mixture was incubated in dark condition at room temperature for 20 
minutes. After 20 minutes, the absorbance of the mixture was read at 517nm. 
3ml of DPPH was taken as control. 
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                                       Abs (control) - Abs (test) X 100 
         % Inhibition =   
                                                              Abs (control) 
 
ANTI MICROBIAL STUDIES 
ANTIBACTERIAL ACTIVITY  
The different extracts of whole plant of Indigofera  aspalathoides were subjected to 
antibacterial studies against gram positive and gram negative organism. 
The organism used were96  
   Gram positive organism 
Enterococcus 
Staphylococcus aureus 
 Gram negative bacteria 
E-coli 
Pseudomonas aeruginosa 
Proteus mirablis 
 MEDIUM: 
            Muller Hinton agar. 
PREPARATION OF THE BACTERIAL SUSPENSION FOR INOCULATION: 
Few colonies of the pathogenic strains were picked up and inoculated into 4ml of 
peptone water. These tubes were incubated for 2-5hours to produce a bacterial 
suspension. The suspension was then diluted if necessary with saline solution to 
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density, which is visually equivalent to that of standard prepared by adding 0.5ml 
of 1% barium chloride to 99.5ml of 1% sulphuric acid. This suspension was then 
used as inoculum of bacteria. 
PREPARATION OF MUELLER HINTON AGAR (MH AGAR): 
 
1. Beef infusion - 30g/I 
2. Casein acid hydrolysate  - 17.5g/I 
3. Starch - 1.5g/I 
4. Agar - 17g/I 
 
38g of Muller Hinton agar was weighed and dissolved in 100ml of distilled water and 
adjusted to pH 7.3±0.2 sterilized by autoclave at 121℃ at 1516 pressure for 15mins 
and used for the sensitivity test 97. 
 
PREPARATION OF AGAR PLATES: 
The extracts were poured into Muller Hinton agar medium such that the final 
concentration of extraction is in equal volume to that of the original. 
 
PROCEDURE: 
MINIMUM INHIBITORY CONCENTRATION: 
The plates were prepared using agar and different extracts of various dilutions and it 
is allowed to solidify and dry. The suspensions of bacterial colonies were inoculated 
into the plate. Then the plates were incubated at 37∘C for 24hours and then results are 
recorded. 
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ZONE OF INHIBITION:  
A suitable dilution of a broth culture or a broth suspension of the test bacterium or 
fungi is flooded on the surface of a solid medium (MH agar). The plate is tilted to 
ensure uniform spreading and the excess broth pipetted off. Inoculations may also be 
performed by spreading with swabs. After drying the plates (37∘C for 30mins) 
antibiotic are applied with sterile syringe in the well. After overnight incubation, the 
degree of sensitivity is determined by measuring the zones of inhibition of growth 
around the well. 
STANDARD DRUGS: 
1.Ciprofloxacin 
2.Gentamycin 
3.Cefotaxime 
Ciprofloxacin: 
It is a fluoroquinolone derivative with their broad antimicrobial activity. The bacteria 
develop resistance to fluoroquinolones due to the mutation. 
Mechanism of action 
They act by inhibiting DNA gyrase (topoisomerase II) and DNA topoisomerase IV. 
The former action is direct and leads to an arrest of DNA replication. The later action 
also arrests DNA replication but by blocking the enzyme‟s normal function of 
delinking the daughter DNA molecule. 
Gentamycin: 
This is the aminoglycoside antibiotic is produced by Micomonospora purpura. 
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Mechanism of action: 
It diffuses through outer cytoplasmic membrane and is transported to ribosome. 
Ribosomes manufacture enzyme as per the direction from messenger RNA. It binds 
to 30S ribosomes and interferes with initiation of protein synthesis, block the 
translation of m RNA and prematurely terminate the synthesis. 
Cefotaxime: 
These are cephalosporin, they are active against gram positive and gram 
negative bacteria. The gram negative organisms susceptible to these antibiotics 
include E.coli, Proteus, etc. 
Mechanism of action: 
They act by inhibiting bacterial cell wall synthesis 98. 
 
                       ANTIFUNGAL ACTIVITY  
The different extracts of whole plant of Indigofera  aspalathoides were subjected to 
antifungal studies against Candida albicans. 
MEDIUM: 
       Muller Hinton agar 
PROCEDURE: 
MINIMUM INHIBITORY CONCENTRATION: 
The plates were prepared using agar and different extracts of various dilutions and it 
is allowed to solidify and dry. The suspension of fungus was inoculated into the plate. 
Then the plates were incubated at 37∘C for 24hours and then results are recorded. The 
reports were recorded 99 
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         8.2  RESULTS AND DISCUSSION 
       IN-VITRO ANTIOXIDANT ACTIVITY(DPPH ASSAY) 
 TABLE NO: 10 PERCENTAGE INHIBITION OF EXTRACTS-DPPH  
ASSAY    
 
Extract 
% Inhibition at various concentrations 
10 
µg/ml 
20 
µg/ml 
40 
µg/ml 
80 
µg/ml 
100 
µg/ml Ascorbic acid 61.03 68.88 75.04 82.04 88.31 
Chloroform 35.20 46.07 53.24 59.77 62.08 
Ethyl acetate 39.48 49.09 56.52 61.84 67.31 
Ethanol 56.09 62.15 68.23 73.01 79.53 
 
        FIG NO: 22 GRAPHICAL DATA OF PERCENTAGE INHIBITION 
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In DPPH assay the scavenging potential of the antioxidant compounds or extracts 
were found. The percentage inhibition of Chloroform, Ethyl acetate and Ethanol 
was found to be 58.76, 62.08, 67.31 and 79.53 respectively at a maximum 
concentration of 100µ g/ml. The percentage inhibition of Ascorbic acid 
(Standard) was found to be 88.31. In that ethanol extract showed the maximum 
percentage of inhibition which is comparable to the standard. 
Minimum inhibitory concentration of various extracts of indigofera 
aspalathoides for antibacterial activity and antifungal activity (table.no.11) 
 
  Conc.    Microorganism used    
S.No Extract µg/ml 
          
 1    2 3  4  5  6 
             
1. Chlorofom 100  +  + +    +  +  + 
  200  +   + +     +  -  - 
  300  +   - -     +  -  - 
  400  -   - -      -  -  - 
  500  -   - -      -  -  - 
             
2. Ethyl 100  +   + +     +  +  + 
 Acetate 200  +   + +     +  -  - 
  300  +   - -     +  -  - 
  400  -   - -      -  -  - 
  500  -   - -      -  -  - 
             
3. Ethanol 100  +   + +     +  +  + 
  200  +   - +     +  -  - 
  300  -   - -      -  -  - 
  400  -   - -      -  -  - 
  500  -   - -       -  -  - 
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       1.Staphylococcus aureus      (+) Presence of colonies 
2.Enterococcus  
3.E.coli                 (-) Absence of colonies 
    4.Pseudomonas aeruginosa 
   5.Proteus mirablis 
  6.Candida albicans 
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MINIMUM INHIBITORY CONCENTRATION OF VARIOUS 
EXTRACTS OF  Indigofera aspalathoides FOR ANTIBACTERIAL 
AND ANTIFUNGAL ACTIVITY 
   
                       Control and water 
 
                  
 
 
 
Minimum inhibitory concentration of chloroform extract in 
different concentration (FIG:23) 
 
 
 
 
SELECTION OF ACTIVE EXTRACT 
 
DEPARTMENT OF PHARMACOGNOSY, MMC Page 72 
 
 
Minimum inhibitory concentration of ethyl acetate extract in  
different concentration(FIG :24) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  Minimum inhibitory concentration of ethanol extract in       
different concentration(FIG:25 ) 
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Zone of inhibition of various extracts of  indigofera aspalathoides  for 
antibacterial activity 
 
(table.no.12 
 
NAME OF 
THE  ZONE OF INHIBITION(mm)  
STANDARD/ 
     
     
EXTRACT E-Coli Staphylococcu Proteus Psuedomonas Enterococcus 
  s aureus Mirablis Aureginosa  
      
STANDARD      
Cefotaxime    22      37   30   30   37 
Ciprofloxacin    18     24    35   50   30 
Gentamycin    21    28   36    20   32 
EXTRACT      
Chloroform     6       7    6     13   10 
Ethyl acetate 
extract    20      28   13    11   18 
Ethyl alcohol 
extract     7        15    25    20   20 
Water resistant resistant Resistant Resistant Resistant 
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Zone of inhibition of various extracts of indigofera 
aspalathoides for antibacterial activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zone of inhibition against E-Coli various extracts of  
Indigofera aspalathoides (FIG :26 ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zone of inhibition against Pseudomonas various extracts of 
Indigofera aspalathoides (FIG:27) 
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Zone of inhibition against Proteus various extracts of Indigofera 
aspalathoides (FIG :28) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Zone of inhibition against Staphylococcus  various extracts of Indigofera 
aspalathoides(FIG:29) 
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Zone of inhibition against Enterococcus in various extracts of Indigofera  
aspalathoides (FIG:30) 
 
 The antimicrobial activity of Indigofera aspalathoides extracts werecarried 
out by in vitro method in agar plate against 5 bacterial strains and one fungal 
strain which showed an inhibition of microbial growth of different extracts of  
whole plant. 
 The minimum inhibitory concentration of the ethanol extracts was found to 
be 300µg/ml against the tested microorganism which was found to be more 
effective when compared to other extracts. 
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 The ethanolic extracts of the plant showed better antibacterial activity 
against Pseudomonas, Proteus And Enterococcus by exhibiting almost 
equal zone of inhibition compared to that of standard drug Gentamycin. 
The plant extracts showed good antifungal activity with minimum inhibitory 
concentration of about 300µg/ml for the ethanol and chloroform extracts. 
 The antimicrobial studies of various extracts of the Indigofera  
aspalathoides confirms its benefits to be used in the remedies of the diseases 
caused by these organisms. 
 
  
 
 
 
 
 
FORMULATION AND EVALUATION  
 
 
 
 
 
 
                                  FORMULATION AND EVALUATION 
 
DEPARTMENT OF PHARMACOGNOSY, MMC Page 78 
 
9. FORMULATION AND EVALUATION OF HERBAL     
OINTMENT 
   9.1   MATERIALS AND METHOD      
   Formulation Of Herbal Ointment100 
         Ingredients: 
          Bess wax                 -   2g 
          Liquid paraffin      -   1g 
          Methyl  paraben    -   0.02 
         Propyl  paraben       -0.02 
        METHOD:   
Bees wax and  liquid paraffin  were  heated  separately  in a china dish at 70℃. 
Methyl paraben and propyl paraben were mixed separately. Bees wax and 
liquid paraffin mixture was  added drop by drop with constant  stirring  to 
form a ointment base.   
       Preparation  of herbal ointment I 
            Ointment base   -3g 
            Ethanol extract  -.02g 
          The above the ingredients  were mixed together and stirred 
    
         Preparation  of herbal ointment II 
            Ointment base   -3g 
            Ethanol extract  -.04g 
        The above the ingredients  were mixed together and stirred                       
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EVALUATION OF THE  OINTMENT101 
Physical Examination: 
The prepared ointment formulations were inspected visually for their colour, 
homogeneity, consistency. 
Determination of pH: 
2.5gm Ointment sample was taken in 100 ml dry beaker, 50 ml water was added to it. 
Beaker was heated on water bath maintained at about 60ºC to 70ºC for 10 minutes, 
cooled to room temperature  and then centrifuged at 3000 rpm for 10 minutes. The pH 
of water extract was measured by using pH meter. The pH measurements  was done 
by using a digital type pH meter by dipping the glass electrode into the ointment 
formulation. 
3. Extrudability: 
       Ointments were filled into collapsible tubes after formulating them and 
extrudability was determined. 
4. Rubout 
 It included spreadability and wetness. A 0.1g of ointment  was applied on dorsal skin 
surface of human volunteer and the properties were observed . 
5. Skin sensitivity test  
  The ointment was applied on the shaved intact skin of  Albino mice and examined 
for any changes on the skin after 24hrs. 
                        
 
 
 
                                  FORMULATION AND EVALUATION 
 
DEPARTMENT OF PHARMACOGNOSY, MMC Page 80 
 
 
                   9.2   RESULTS  AND  DISCUSSION 
     1. Physical Appearance: 
Ointment formulations were pale green viscous preparation with a smooth 
homogeneous  texture. The Physical Appearance of the ointment were given in 
Table no: 13 
                                Table no :13 Physical Appearance 
    S.No Formulations Colour Homogeneity Consistency 
     
1 2%w/w pale green Excellent +++ 
     
2 4%w/w pale green Excellent +++ 
     
     
 
 
2.Determination of pH: 
The pH of the ointment solution was measured with the help of pH meter. 0.5g of 
ointment was dissolved in 50ml of distilled water and stored for two hours. The 
measurement of pH each formulation was done in triplicate. 
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                            Table no :14 pH of ointment 
               
S.no. Formulations pH 
   
1 2%w/w 6.36±0.3 
2 4%w/w 6.27±0.1 
 
3.Extrudability: 
Ointments were filled into collapsible tubes after formulating them. The extrudability 
of the formulation has been checked. 
                   Table no :15  Extrudability of ointment 
 
S. No. Formulations Extrudability 
   
1 2%w/w Easily Extrudable 
   
2 4%w/w Easily Extrudable 
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            4. Spreadability   
     Spreadability  of the ointment on  skin surface of human volunteers were   
givenin table no:16 
                         Table no :16 Spreadability   of ointments 
S. No. Formulations Spreadability 
   
1 2%w/w Good 
   
2 4%w/w Good 
   
 
  5. Skin sensitivity test  
     The skin sensitivity showed  no irritation ,redness or erythema indicating that both 
ointments were non-irritant. 
                              Table no :17 skin sensitivity test of ointments 
S. No. Formulations Skin test 
   
1 2%w/w non irritant 
   
2 4%w/w non irritant 
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                      10. ANTI- PSORIATIC ACTIVITY101,103 
10.1 Materials and Methods 
Imiquimod Cream Induced Psoriasis Model 
Plant extract 
 Ethanolic extract ointment  of whole plant  of  Indigofera  aspalathoides   
Animal selection and procurement 
 Healthy Albino mice (weighing about 18 – 25 g) were procured from the Madras 
Medical College animal house. The animals used for the entire study was approved by 
the Institutional Animal Ethical Committee which is certified by the Committee for 
the purpose of control and supervision of experiments on animals, India. 
Approved CPCSEA Registration No  : IAEC/MMC/09/2016         Dated: 21/11/2016. 
 The procured animals were kept in a clean, dry polycarbonate cages and maintained 
in a well-ventilated animal house. The temperature of experimental animal room was 
maintained at 22ºC (± 3ºC) and the relative humidity was maintained from 50-60%. 
Lighting was artificially maintained for 12hrs dark and 12hrs light. All the animals 
were kept in the cages for at least 5days prior to dosing for acclimatization to the 
laboratory conditions. The animals were fed with standard pellet diet and water was 
given ad libitum. Before starting the dose, the animals were fasted overnight but 
allowed to access water. 
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EXPERIMENTAL DESIGN:  
Grouping of animals:  
                                        TABLE NO: 18 Grouping of animals 
  
S.NO 
 
 
   GROUPS 
 
NO.OF ANIMALS  
1 
 Control group 
       6 
2 
Disease control 
       6   
3 
Standard 
        6 
4 
Test group-I 
       6 
5 
Test group-II 
       6 
      TOTAL        30 
                                                                   
Psoriasis induction104 
       5%  Imiquimod cream 
Procedure 
Mice at 8–10 weeks of age were used in this experiment. The mice were divided into 
five  groups  such as  group I,  II,  III,  IV, V .  Back skin of the mice was shaved and 
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remaining hair were   removed using a depilatory cream (Veet). Shaved back skin 
were daily treated with 62.5 mg Aldara©cream (5% Imiquimod, 3M Pharmaceuticals) 
for 6 days. Control mice were treated similarly with Vaseline .Severity of skin 
inflammation was evaluated using a clinical score based on Psoriasis Area Severity 
Index as erythema, scaling and thickening were scored on a scale from 0 to 4 (0: 
none; 1: slight; 2: moderate; 3: marked; and 4: severe) used to measure the severity of 
inflammation. 
Treatment of animal groups 
GROUPS        TREATMENT 
SCHEDULE   
NUMBER OF ANIMAL 
1. Control group  vaseline  for 15day     6 
     
2.Disease control  Imq for  6days     6 
 
3.Standard  Imq(6days) +clobetasol  
for     15days 
    6  
4.Test group-I    Imq(6days) + low  dose 
ointment( 2%w/w) for 15 
days 
    6 
5.Test group-II   Imq(6days) + high dose 
ointment( 4%w/w) for 
15days 
     6 
                                
                                                    Total 
 
    30 
               TABLE NO:19 treatment of animal group 
The standard and ointments were applied topically once daily for 2 weeks , drugs   
were applied topically. Two hours  after the last treatment the animal were sacrificed , 
longitudinal sections of the  skin were made.   
Histopathological examination  
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  The longitudinal sections of the  skin fixed in 10% formalin embedded in paraffin 
and cut into 5 µm thick section using a microtome. Sections are mounted on glass 
slides using standard techniques. The sections are stained with Haematoxylin-eosin 
and are examined under a microscope using 10 × magnifications and photographed 
under a light microscope equipped for photography.  
PARAMETERS EVALUATED105,106 
1. Drug activity and percentage orthokeratosis 
 Drug activity and percentage of orthokeratosis(ok) in those parts of the adult mouse 
skin, which  normally have a parakeratotic differentiation, was quantified measuring 
the length of the granular layer (A) and the length of the scale (B).  
 
% Orthokeratosis = (A/B) × 100  
 
   %activity    =    Mean OK of treated group - Mean OK of control group × 100 
                                              100 - Mean OK of the control group 
      OK= orthokeratosis 
 10 sequential scales per animal were measured and the results were given in % 
orthokeratosis  per scale. Individual orthokeratosis values were obtained per test 
group.  
2. Epidermal thickness  
      It was obtained by measuring the distance between the dermo epidermal 
borderline and the beginning of the horny layer. Five measurements per animal were 
made in every 10 scales and the mean of the different animals was calculated. The 
change in epidermal thickness was then calculated.  
PHARMACOLOGICAL  STUDIES 
 
DEPARTMENT OF PHARMACOGNOSY, MMC. Page 87 
 
         
 
 
Epidermal thickness  =  ET of treated group -  ET of control group × 100 
                                                                  100 - ET of the control group 
    
ET = Epidermal thickness 
Statistical analysis  
Results were expressed as Mean ± SEM. The data was analyzed using one way 
analysis of variance (ANOVA) followed by Dennett’s test. P values < 0.01 were 
considered as Significant. 
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                                 10.2 RESULTS  AND DICUSSION 
Anti-psoriatic activity of the herbal ointment formulated with whole plant of 
Indigofera aspalathoides. were carried out by mice skin model and result are 
summarized as follows, 
INDUCTION OF PSORIASIS 
IMQ-induced skin inflammation in mice phenotypically resembles psoriasis. 
Erythema, scaling, and thickness of the back skin was scored daily on a scale from 0 
to 4. Scores are measured the result are summarized as follows. 
  
     Control animal fig:31                            Disease control  fig :32 
     
    Standard animal fig:33                     Test 1 animal fig :34  
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              Test 2 animal fig :35 
            Table no:20 Scaling of  mice skin           
         
 
 
 
                      Fig :36 Scaling of  mice  skin  
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Days                    Scaling 
Control 
group 
Disease 
group 
Standard 
group 
Test 1 
group 
Test 2 
group 
1 0 0 0 0 0 
2 0 1±0.16 1±0.16 1±0.16 1±0.16 
3 0 2±0.31 1±0.16 1±0.16 2±0.31 
4 0 3±0.50 2±0.31 2±0.31 2±0.31 
5 0 4±0.66 3±0.50 4±0.66 3±0.50 
6 0 4±0.66 3±0.66 4±0.66 4±0.66 
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               Table no:21   Erythema of  mice skin 
Days                     Erythema 
Control 
group 
Disease 
group 
Standard 
group 
Test 1 
group 
Test 2 
group 
1 0 0 0 0 0 
2 0 1±0.16 1±0.16 1±0.16 1±0.16 
3 0 2±0.31 1±0.16 1±0.16 2±0.31 
4 1±0.16 3±0.51 2±0.31 2±0.31 2±0.31 
5 1±0.16 4±0.66 3±0.50 4±0.66 3±0.50 
6 1±0.16 4±0.66 3±0.50 4±0.66 4±0.66 
 
                        Fig: 37   Erythema of  mice skin 
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                               ANTI PSORIATIC ACTIVITY 
  
                       
    Control animal fig:38                                          Disease control animal fig: 39  
            
Standard(clobetasol) animal                                    Test 1(2%w/w ointment)animal     
            Fig:40                                                                            fig :41 
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       Test2 (4%w/w ointment)animal fig :42                     
     HISTOPATHOLOGICAL EVALUTION OF THE MICE SKIN 
   
       
                                             
                                               FIG:43 CONTROL  MICE SKIN  
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                                            FIG:44 DISEASE CONTROL  MICE SKIN 
   
 
                       FIG:45 STANDARD MICE SKIN 
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                 FIG:46     TEST 1(2%W/W OINTMENT) MICE SKIN 
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                FIG:47 TEST-2(4%W/W OINTMENT) MICE SKIN 
% of orthokeratosis in mice skin Table:22 
Animal groups % of orthokeratosis 
Control     55 ± 1.2 
Disease      5± 2.1** 
Standard      60± 1.8*** 
Test1 low dose (2%w/w)     30± 2.0** 
Test 2 high dose(4%w/w)     53±1.5*** 
 
Values are mean ± SEM  Statistical significant test for comparison was done by 
ANOVA, followed by Dunnet’s ‘t’ test (n=6). **P< 0.01, *P< 0.05 when compared 
against control. 
 
      % of orthokeratosis in mice skin fig:48 
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% of epidermal thickness in mice skin Table:23  
Animal groups % of epidermal thickness 
Control 9±.052 
Disease 40±0.70** 
Standard 7±0.42*** 
Test1 low dose (2%w/w) 19±0.71** 
Test 2 high dose(4%w/w) 10±0.32*** 
 
Values are mean ± SEM  Statistical significant test for comparison was done by 
ANOVA, followed by Dunnet’s ‘t’ test (n=6). **P< 0.01, *P< 0.05 when compared 
against control. 
 
% of epidermal thickness in mice skin fig:49 
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Discussion: 
      The ethanolic extract ointment (high dose4%w/w) showed increased  
orthokeratosis  percentage   and  decreasd  epidermal thickness  regions.  The standard 
drug clobetasol  showed the increased orthokeratotic  and decrease epidermal 
thickness  regions. Respectively in comparison to normal and imq treated skin. At 
present ,psoriasis remain pathology for which no complete cure  is available . 
Corticosteroid treatment, which lead to a quick remission of symptoms , must be used 
for a short term because of its serious  adverse effects. Therefore, it thus remains as a 
valuable therapeutic objective to find out a compound with some of the beneficial 
properties  of the anti-psoriatic drugs but without their deleterious effects. 
In this aspect ,the herbal ointment  formulated with ethanolic extract of Indigofera 
aspalathoides show prominent anti-psoriatic activity with 53 ±1.5% of orthokeratosis 
and  10 ±0.32%  epidermal thickness activity in mice skin which is comparable to the 
standard (clobetasol). 
 
 
  
 2 
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                   11. SUMMARY AND CONCLUSION 
Indigofera aspalathoides plant is used in traditionally in  the treatment of skin disease. The 
literature survey indicates that no scientific data on the anti-psoriatic activity of this plant. 
Various parts of this plant have been claimed to be effective in a wide range of disease. 
The allopathic drugs like methotrexate, corticosteroids and immune suppressants shows 
effective response in psoriasis by reducing the scales, plaque, cell proliferation and 
inflammation but the adverse reaction is severe than the efficacy of the drug. The long term 
usage of drug causes serious adverse reaction like hepatotoxicity, renal failure sometimes 
lead to fatality. So  herbal drugs are safe in psoriasis treatment since the adverse effect is mild 
or nil and lower the cost of therapy as comparable to the allopathic medicine. 
The morphological and physiochemical properties of the whole plant were evaluated. 
Different extract of whole plant powder were prepared and these extracts were subjected to 
phytochemical evaluation. The ethanolic extract showed the presence of various  phyto 
constituents such as ,Steroids, flavonoids, alkaloids and carbohydrates. 
All the extract was tested for anti-microbial activity. Ethyl acetate and ethanol extract showed 
good activity even at low concentration and also shows maximum zone of inhibition. 
The ethanolic extract were formulated as an ointment in a concentration of 2%w/w and 
4%w/w evaluated for anti-psoriatic activity. The ointment were then pharmacologically 
evaluated for their anti psoriatic activity using mice skin model test. The ointment prepared 
with ethanolic extract showed antipsoriatic activity which was comparable to the standard 
clobetasol cream. The activity of ethanol extract cream was seen to be superior to standard 
ointment. 
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The ethanolic extract was subjected to HPTLC finger printing to establish an identity for 
future comparison. An attempt was also made to isolate the active constituents from the 
ethanol extract. 
The present study confirms the anti-psoriatic activity of ethanol extract of Indigofera 
aspalathoides., whole plant by various studies including in vitro and in vivo as mentioned in 
the study .The efficacy of the ointment could also be evaluated for clinical settings. 
                    
                                FUTURE SCOPE  
 1. Quantification of major phytoconstituents 
2. Isolation of the responsible compounds for the activity 
3. Clinical trails may be performed on psoriatic patients 
4. Large scale manufacturing and marketing may be taken up based on     
clinical trails evaluation 
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